{"filing":{"accession_number":"0001213900-26-088411","cik":"0002023016","ticker":"TTRX","company_name":"Turn Therapeutics Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"ea0301772-8k_turn.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2023016/000121390026088411/ea0301772-8k_turn.htm"},"events":[{"id":27305,"run_id":24870,"accession_number":"0001213900-26-088411","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Turn Therapeutics issued a press release on August 12, 2026 announcing financial and operating results for the quarter ended June 30, 2026, including consolidated statements of operations and selected balance sheet data. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The filing includes quarterly financial metrics (operating expenses, net loss, loss per share, cash position) and is material to investors assessing the company's financial condition and operational progress.","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28768,"accession_number":"0001213900-26-088411","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Turn Therapeutics issued a press release on August 12, 2026 announcing financial and operating results for the quarter ended June 30, 2026, including consolidated statements of operations and selected balance sheet data. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The filing includes quarterly financial metrics (operating expenses, net loss, loss per share, cash position) and is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:42:37.966923+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28768,"accession_number":"0001213900-26-088411","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Turn Therapeutics issued a press release on August 12, 2026 announcing financial and operating results for the quarter ended June 30, 2026, including consolidated statements of operations and selected balance sheet data. The disclosure is filed under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for earnings releases. The filing includes quarterly financial metrics (operating expenses, net loss, loss per share, cash position) and is material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T20:42:37.966923+00:00","company_name":"Turn Therapeutics Inc.","ticker":"TTRX","filing_date":"2026-08-12"}]}